Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.554 EUR | -0.11% | +0.83% | +7.88% |
Jul. 01 | UBS Upgrades Rentokil Initial to Neutral from Sell, Boosts PT | MT |
Jul. 01 | Berenberg raises Centrica; UBS likes Rentokil | AN |
Strengths
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.13 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RTO Stock
- RTO1 Stock
- Ratings Rentokil Initial plc